Radiographic Severity Scoring System and Clinical and Laboratory Evolution of COVID-19 Pneumonia

What this Trial Is About

Researchers are performing a retrospective study to examine patients admitted to the COVID-19 ICU at the University Hospital Osijek during 2020 and 2021 with pneumonia caused by the SARS-CoV-2 virus. The study aims to explore the relationship between changes seen in chest x-rays and variations in laboratory markers of inflammation and respiratory function. The research involves reviewing medical histories to gather data on patient comorbidities, hospital stays, respiratory support, and final outcomes. The study involves analyzing chest x-rays using the Brixia scoring system to quantify lung inflammatory infiltrates at different treatment stages, including hospital admission and time in the Respiratory Center. Laboratory tests such as inflammatory markers (CRP, procalcitonin, IL-6, ferritin), blood cell counts, blood urea nitrogen, arterial blood gases, and ventilation parameters are recorded at multiple points during ICU care. Additional data include the use of antibiotics, bacterial infections, sepsis, and organ failure occurrences. Participants' medical records are reviewed to collect clinical and laboratory data. Radiology specialists evaluate chest x-rays to score lung severity, while clinical scores like SOFA and APACHE II are calculated upon ICU admission. Outcome measures focus on chest x-ray severity scores and inflammatory markers over 21 days. The study helps understand how lung imaging changes correlate with inflammation and respiratory status throughout ICU treatment for COVID-19 pneumonia.

Retrospective Analysis of Chest X-ray Severity Scoring System of COVID-19 Pneumonia